Stock analysts at JPMorgam Chase& Co. started coverage on shares of Teva Pharmaceutical Industries in an investigative study put into a report that was issued on Monday, MarketBeat.com states. The firm set an “overweight” rating and a $82.00 price point on the stock. JPMorgan Chase & Co.’s price goal implies a possible upside of 17.04% from the company’s last close.
Some other equities research analysts have as well weighed in on the business. Sanford C. Berstein raised Teva Pharmaceutical industries to a “buy” rating and set a $80.00 price point for the business in a study note back on Tuesday, July 28th. Morgan Stanley assumed coverage on Teva Pharmaceutical Industries in a research note back from Wednesday, July 29th. They set an “overweight” rating and a $85.00 price point for the business.
RBC Capital raised their price point on Teva Pharmaceutical Industries from $75.00 to $85.00 and gave the company an “outperform” rating in an investigative study documented on Wednesday, July 29th. Oppenheimer reissued an “outperform” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday. In conclusion, Leerink Swann reassured a “buy” rating set a $83.00 price point on shares of Teva Pharmaceuticals Industries in an investigative study documented on Friday.